LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Kazia Therapeutics Limited

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERKZIA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / KZIA COVERAGE

What’s moving Kazia Therapeutics Limited now

Current reporting with the operating signal separated from the noise.

01
TradingView

Price to earnings forward of Kazia Therapeutics Limited – NASDAQ:KZIA

Investors are testing whether Kazia Therapeutics Limited’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
TradingView

Kazia Therapeutics Limited Revenue Breakdown – NASDAQ:KZIA

Investors are testing whether Kazia Therapeutics Limited’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Kazia Therapeutics Limited: Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited: Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

The story matters when it changes Kazia Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer

The story matters when it changes Kazia Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Depositary Receipt (KZIA) Price Target Increased by 17.86% to 16.83

Kazia Therapeutics Limited

The story matters when it changes Kazia Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest KZIA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-07-28 · Period 2026-07-28SEC ↗6-KOfficial SEC filingFiled 2026-06-02 · Period 2026-06-02SEC ↗424B3Official SEC filingFiled 2026-07-28SEC ↗424B3Official SEC filingFiled 2026-07-28SEC ↗424B3Official SEC filingFiled 2026-07-28SEC ↗424B3Official SEC filingFiled 2026-07-28SEC ↗4Official SEC filingFiled 2026-07-08 · Period 2026-01-08SEC ↗4Official SEC filingFiled 2026-07-08 · Period 2026-01-08SEC ↗
EARNINGS / QUARTERLY TRACKER

Kazia Therapeutics Limited, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.